Overview

A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia

Status:
Terminated

Trial end date:
2020-01-14

Target enrollment:

Participant gender:

Summary

This study is a Phase 2 multicenter, randomized, open-label, parallel-group study. The primary objective of the study is to evaluate the effect of LJPC-401 (synthetic human hepcidin) on iron levels in patients with transfusion-dependent beta thalassemia with myocardial iron overload.

Phase:

Phase 2

Details

Lead Sponsor:

La Jolla Pharmaceutical Company

Treatments:

Hepcidins